The FAS has opened a case against the KRKA pharmaceutical company. The service sees in the activities of the organization signs of the establishment of monopolistically high prices for the drug "Ko-Dalneva".
As stated in the FAS message, in case of recognition of a violation, the company faces a fine in accordance with the Administrative Code of the Russian Federation.
The drug "Ko-Dalneva" is used for high blood pressure.
KRKA is a generic pharmaceutical company.
Russia is one of the 6 countries where KRKA has its own pharmaceutical production. This is one of the key markets of KRKA, according to the company's website.
